Diaceutics (LON:DXRX) Earns “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX) in a research note released on Tuesday, MarketBeat Ratings reports. Canaccord Genuity Group currently has a GBX 160 ($2.11) price target on the stock.

Diaceutics Price Performance

LON:DXRX opened at GBX 133 ($1.76) on Tuesday. Diaceutics has a 52-week low of GBX 82 ($1.08) and a 52-week high of GBX 136 ($1.80). The company has a quick ratio of 9.92, a current ratio of 6.40 and a debt-to-equity ratio of 2.95. The firm has a market cap of £112.33 million, a P/E ratio of -6,650.00 and a beta of 0.58. The business’s 50-day moving average price is GBX 128.68 and its 200 day moving average price is GBX 118.03.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.